HIV/AIDS News

Exposure to HIV treatment in utero may increase infants’ risk for development deficiencies and reduced performance of the heart during childhood, according to recent study data.

A total of 28 mayors from cities heavily affected by HIV/AIDS recently signed a declaration in Paris to end the epidemic in their communities by 2030, according to a press release.

The percentage of reported HIV-positive patients with tuberculosis receiving ART increased from 37% in 2009 to 69% in 2013, CDC researchers reported in MMWR.

Mylan today announced it has received tentative FDA approval for a fixed-dose combination of abacavir and lamivudine to treat HIV-1 among children.

The CDC’s Advisory Committee on Immunization Practices and the AAP have updated recommendations for use of the 13-valent pneumococcal conjugate vaccine among children aged 6 to 18 years with an increased risk for invasive pneumococcal disease.

Data from a retrospective study conducted in seven African countries with a predominantly young female cohort indicated adolescents were less likely to follow up with ART compared with older adults.

Women who received a three-drug regimen during pregnancy were less likely to transmit HIV to their child compared with women who received one drug during pregnancy and two more after birth, according to an NIH press release.

Recent data indicate antiretroviral exposure in utero posed a small increased risk for infants, suggesting the benefits of recommended ART during pregnancy outweighs risks.

Longer duration of viral suppression was associated with younger age at combination ART initiation among children with perinatal HIV, according to study findings published in JAMA Pediatrics.

Recent data show children who received antiretroviral therapy at a higher CD4 percentage and younger age were more likely to experience immunologic recovery than their older peers with lower CD4 percentage.